雅本化學(300261.SZ)控股股東解除質押50萬股
格隆匯12月20日丨雅本化學(300261.SZ)公佈,公司近日接到控股股東雅本投資的通知,雅本投資將其所持有的50萬股公司股份辦理了解除質押業務,佔其所持股份比例的0.17%,佔公司總股本的0.05%。
雅本投資未來半年內到期的質押股份累計數量為8846.5048萬股,佔公司控股股東所持股份比例為30.16%,佔公司總股本比例為9.18%,對應融資餘額約1.656億元。
雅本投資未來一年內到期的質押股份累計數量為2.07億股,佔公司控股股東所持股份比例為70.72%,佔公司總股本比例為21.53%,對應融資餘額約4.21億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.